Kornimate/medical-research-clean huggingface dataset:
effect of kinesiotaping versus endurance exercise on postmenopausal low back pain

Conditions: Low Back Pain

Summary: this study will be conducted to determine the effect of kinesiotaping versus endurance exercise on postmenopausal low back pain.

non-specific back pain is more frequent in women than men, mainly in postmenopausal women. high prevalence of hypovitaminosis d has been detected in postmenopausal women, and it is associated with decreased bone mass, sarcopenia, which can be related to back pain. postural control, can be defined as "the ability to maintain the body's center of gravity within the limits of stability as determined by the base of support , differences in motor behavior between low back pain (lbp) patients and healthy control subjects have been demonstrated in a variety of tasks, e.g. during walking and in response to several perturbations. published evidence indicates that lbp patients may have impaired control over trunk posture and movement, dynamic controls is important in many functional tasks as it requires integration of appropriate levels of proprioception, range of motion, and strength. endurance exercise is characterized by continues submaximal muscular contractions . it is an effective mean of maintaining or improving cardiovascular and musculoskeletal health, both of which are critical for preserving physiological functioning, independence and improving standing balance. kinesiotape allows the joint to move through its full range of motion. it has also been reported to increase blood circulation and lymphatic drainage, which leads to a reduction of pain and stimulates large-fibre cutaneous mechanoreceptors that may inhibit proprioceptive impulses in the spinal column and decrease pain via an ascending pathway.

Eligibility criteria:
inclusion criteria: * a convenient sample of fifty postmenopausal women suffering from non-specific low back pain and postural instability was enrolled in this study. * praticipants were chosen healthy and medically stable. * their ages ranged from 50 - 60 years to be included in the study. * their body mass index (bmi) is not exceed 35 kg m2. * all of them are diagnosed by the gynecologist. exclusion criteria: * they were excluded from the study if they had: * premature menopause or surgical menopause. * mental , neurological , vestibular , cardiovascular disorders, metabolic disease. ----- * musculoskeletal disorders ( disc lesion , ankylosing spondylitis , rheumatoid arthritis , osteomalacia , spinal deformities, lumber vertebre fractures) .

Keywords: kinesiotape endurance exercise postmenopausal low back pain.
deep transcranial magnetic stimulation (dtms) as a treatment for attention deficit hyperactivity disorder (adhd) in adults

Conditions: Attention Deficit Hyperactivity Disorder

Summary: the aim of the study is to assess the effect of left or right high-frequency dtms on adhd symptoms, cognitive performance and decision-making ability of adhd adults, and to compare this to the effect of sham dtms on adhd adults

attention deficit disorder in adults may be due to hypoactivity of prefrontal areas of the brain. increasing the activity of these areas may help improve symptoms in many of these patients. in addition there is evidence as to dysfunction in both hemispheres of the brain, but it is difficult to determine the contribution of each hemisphere's pattern of activity to behavioral impairment. the purpose of this study is to use high-frequency dtms to stimulate activity either on the left side of the prefrontal cortex (one arm), or on the right side (a second arm), to see if such stimulation improves attention, comparing to sham dtms simulation (a third arm).

Eligibility criteria:
inclusion criteria: * men and women aged 18-65. * appropriate diagnosis of adhd according to dsm-iv criteria: o dsm-iv criteria require not only that the adhd symptoms be present now (self-report), but also to have been present in childhood (self-report) * subjects taking medications for attention deficit disorder will give their consent to stop the drugs from a week before the start of participation in the study, and during the daily treatment phase (four weeks total); subjects also will be asked not to take these medications 24 hours before participation in the review meetings (4 and 8 weeks after the end of the daily treatment phase). * subjects have given their written and oral consent to participate in research. exclusion criteria: * any dsm-iv axis i psychiatric disorder. * use of antipsychotic stabilizers; other than benzodiazepines if necessary to a daily dosage equivalent to 2 mg lorazepam. * history of lack of tolerance to tms. * diagnosis of severe dsm-iv personality disorder. * current suicidal tendency. * uncontrolled high blood pressure * history of epilepsy, seizures or fever convulsions. * history of epilepsy or convulsions in first-degree relatives. * a history of head injury or a stroke which caused deficits. * history of metal in the head (outside the oral cavity). * history of plastic or metal implants, including metallic particles in the eye, pacemaker, implanted hearing aid devices, use of neurostimulators, or any medical pump. * a history of drug or alcohol misuse. * people who lack judgment or are unable to communicate with the experimenters. * participation in any other medical research during the three months prior to the time of this experiment. * subject's inability to sign a consent form. * pregnancy, or not using contraception.
the role of hif-2a in the pathogenesis of reflux esophagitis

Conditions: Esophagitis; Reflux Esophagitis; Gastroesophageal Reflux Disease

Summary: the purpose of this study is to determine the role of hypoxia inducible factor (hif)-2a on the production of inflammatory cytokines that lead to reflux esophagitis.

reflux esophagitis is thought to be caused by gastric acid that refluxes into the esophagus, causing injury. newer data suggest that reflux of gastric juice into the esophagus stimulates hif-2a, which increases production of inflammatory cytokines. these cytokines are thought to lead to reflux esophagitis. the investigators plan to study the relationship of hif-2a to inflammatory cytokines in patients with known gastroesophageal reflux disease and reflux esophagitis.

Eligibility criteria:
inclusion criteria: * u.s veteran * history of los angeles grade c erosive esophagitis exclusion criteria: * inability to provide informed consent * esophageal varices * warfarin use * coagulopathy that precludes safe biopsy of the esophagus * comorbidity that precludes safe participation in the study * allergy to fluorescein sodium * pregnancy

Keywords: esophagitis reflux esophagitis gastroesophageal reflux disease acid inflammation esophagus cytokines esophageal squamous cell reflux squamous epithelium
does hyaluronic acid affect periodontal treatment?

Conditions: Periodontitis

Summary: objective: the aim of this study is to evaluate the effect of ha as an adjunct to scaling and root planning (srp) on clinical parameters, periodontal inflamed surface area (pisa) and adenosine deaminase (ada), catalase (cat), and glutathione (gsh) levels in gingival crevicular fluid (gcf) in patients with periodontitis.

design: a total of 24 stage ii-iii periodontitis patients will be included in this split-mouth, randomized-controlled study. the study population will be divided into four groups: in group 1 (srp): srp+ saline; in group 2 (srp+hagel): srp + ha gel; in group 3 (srp+hamo): srp+ ha mouthrinse; and in group 4 (srp+hamo+hagel): srp+ha mouthrinse + ha gingival gel were applied. at baseline and week 4 periodontal clinical parameters and pisa will be calculated. also, gcf amount will be collected to evaluate ada, cat, and gsh by spectrophotometric analysis.

Eligibility criteria:
inclusion criteria: * systemically healthy * moderate-to-severe periodontitis * at least five sites with ≥5mm probing depth (pd) * at least ≥20 teeth * stage ii-iii periodontitis according to the 2017 world workshop * age between18-55 exclusion criteria: * receiving systemic or local antibiotics within the past six months * prior surgical or non-surgical periodontal treatment within the past six months * smoking * pregnancy * lactation * age ≤18 years or ≥55 years * hypertension * known chronic systemic diseases (i.e., diabetes mellitus, rheumatoid arthritis), - - known hypersensitivity to one of the ingredients of the ha preparation.

Keywords: periodontitis hyaluronic acid scaling and root planning adenosione deaminase catalase glutathione
assessment of small fiber neuropathy in rare diseases using sudoscan

Conditions: Small Fiber Neuropathy; Fabry Disease; Ehlers Danlos Syndrome; Mitochondrial Disease

Summary: sudoscan™ (impeto medical, paris france) uses electrochemical skin conductance as a novel noninvasive method to detect sudomotor dysfunction. several small studies have recently shown that sudoscan use in the assessment of small fiber polyneuropathy (in diabetes mellitus) can be performed non-invasively, quickly and effectively. the investigators aim to study the use of sudoscan in rare disease condition associated with small fiber polyneuropathy.

small fiber polyneuropathy (sfpn) is diagnosed through a combination of symptoms, signs and confirmatory diagnostic testing. nerve conduction studies are not sensitive enough in most of the cases leaving the ankle skin biopsy with measurement of intraepidermal nerve fiber density (ienfd) as the main diagnostic tool. despite its utility and reproducibility, skin biopsy is invasive, expensive and requires a central laboratory for processing and interpretation. quantitative sudomotor axon reflex testing (qsart) is also routinely used for evaluation of small fiber neuropathy as sudomotor axons can also be involved. this test however remains technically challenging and requires testing conditions in specialized labs that are not always suitable for all patients' population. by comparing findings on skin biopsy and/or qsrt, accepted gold standard for diagnosing sfpn, the investigators seek to find faster, less-invasive ways to diagnose and monitor small-fiber polyneuropathy in rare diseases using sudoscan measurement.

Eligibility criteria:
inclusion criteria: * males and females with confirmed disease: fabry (by gla enzymes and/or dna testing) naïve and on ert, mitochondrial diseases (electron transport chain and/or dna testing) or connective tissue diseases (clinical criteria and/or dna testing when available) * consenting adults (18 years and older) who agrees and consents to skin biopsy and qsart procedure exclusion criteria: * subjects with cognitive, psychiatric, or other problems that preclude informed consent. * patients with history of glucose intolerance or diabetes. * patient on chemotherapy * people with any open or bleeding wounds at any sensor plate contact surface location * people with any type of implantable device * people with missing hand(s) and/or leg(s) * pregnant women or women who are uncertain about a possible pregnancy * patients sensitive to chemicals used to induce sweating * patients with heat intolerance * patients with bleeding disorders * patients on current anticoagulant therapy * patients with keloids on the intended biopsy site * people with hypersensitivity to local amide-type anesthetics
pyrotinib combined with trastuzumab plus aromatase inhibitor in treatment of breast cancer

Conditions: Breast Cancer Female; HER2-positive Breast Cancer; Hormone Receptor Positive Malignant Neoplasm of Breast; Metastatic Breast Cancer; Breast Diseases; Hormone Receptor Positive Tumor

Summary: this study is a single-arm, open-label, phase ii study, comparing the efficacy and safety of pyrotinib plus trastuzumab and aromatase inhibitors, in the treatment of hr (hormone receptor)+/her2 (human epidermal growth factor receptor 2) + mbc and inoperable labc patients.

this is a exploratory, single-arm, open-label,multicenter phase ii trial. our primary purpose is to compare that pfs of patients with pyrotinib plus trastuzumab and ai for her2-positive and hormone receptor-positive mbc or locally advanced breast cancer (labc). in treatment period, patients will be administrated pyrotinib plus trastuzumab and aromatase inhibitors, every 21 days for 1 cycle, until disease progression, toxicity intolerance, withdrawal of informed consent, patients judged must be terminated study termination. the imaging evaluation was performed according to the recist 1.1 criteria every 6 weeks.

Eligibility criteria:
inclusion criteria: 1. age≥18 years,≤70 years, female; 2. postmenopausal or pre-menopausal with ovarian function suppression; 3. with or without measurable lesion evaluable according to response evaluation criteria in solid tumors version 1.1; 4. metastatic or inoperable local advanced invasive breast cancer; 5. her2-positive breast cancer; 6. hr-positive breast cancer; 7. lvef ≥55%;qt interva\<470 ms; 8. eastern cooperative oncology group(ecog) scale 0-1; 9. life expectancy ≥3 months; exclusion criteria: 1. previous systemic non-hormonal anticancer therapy in the metastatic or advanced breast cancer setting; 2. received endocrine therapy within 7 days before randomization;uncontrolled central nervous system metastases; 3. disease-free interval from completion of adjuvant/neo-adjuvant systemic non-hormonal treatment to recurrence of within 6 months. 4. other malignancies within the last 5 years, except for carcinoma in situ of the cervix or basal cell carcinoma. 5. major surgical procedure or significant traumatic injury within 28 days prior to study treatment start or anticipation of the need for major surgery during the course of study treatment 6. severe organ dysfunction as assessed by signs and symptoms, laboratory studies and rapid progression of disease, which leading to a clinical indication for chemotherapy. 7. history of chf of any new york heart association (nyha) criteria, or serious cardiac arrhythmia requiring treatment (exception, atrial fibrillation, paroxysmal supraventricular tachycardia); 8. history of myocardial infarction within 6 months of randomization; 9. history of lvef decline to below 50% during or after prior trastuzumab neo-adjuvant or adjuvant therapy; 10. pregnant or lactating women; 11. qt interval\>470 ms; 12. serious concomitant diseases (including severe hypertension, severe diabetes, active infection, thyroid disease, etc.) that are harmful to the patient's safety or affect the patient's completion of the study;
effect of folic acid supplementation on plasma homocysteine level in obese children

Conditions: Hyperhomocysteinemia; Obesity

Summary: the purpose of the present study was to determine whether folic acid supplementation could reduce plasma homocysteine in obese children and to determine the association between dietary folate, serum folate and homocysteine level through the randomized double blinded placebo controlled trial.

atherosclerosis is common \& remains a significant clinical problem because of leading to myocardial infarction, stroke and cardiovascular death. many studies founded hyperhomocysteinemia is an independent risk factor for those cardiovascular diseases which take responsible for about 10% of total cardiovascular disease risk. reduction of elevated plasma homocysteine may prevent up to 25% of cardiovascular events. one of modifiable cause of hyperhomocysteinemia is prevention of vitamin deficiency, especially folate deficiency. obese thai children are probable risk for folate deficiency due to low dietary folate intake and low serum folate level from unbalanced diet (low vegetables intake \& high fat diet) and high prevalence of thalassemia. moreover obese children are also at risk of atherosclerosis. however, no data have been reported about effect of folic acid supplementation on homocysteine level in these patients.

Eligibility criteria:
inclusion criteria: * patient age between 9-18 years * diagnosed obesity (bmi more than median plus two of standard deviation for age and sex according to who reference 2007) exclusion criteria: * secondary obesity * thalassemia disease * renal and hepatic dysfunction * drugs: anticonvulsant, estrogen, thiazides, metformin, cholestyramine, methotrexate, fibrates, nicotinic acid * previous vitamin supplementation 1 month before study

Keywords: folic acid folate homocysteine obese children
immunogenicity of novel oral poliovirus vaccine type 2 (nopv2), bopv and ipv

Conditions: Polio

Summary: the goal of this clinical trial is to explore two strategies to enhance nopv2 immunogenicity in the field and overcome potential interference of bopv: 1. addition of ipv after one or several doses of nopv2 and bopv to close remaining immunity gaps; 2. separation of bopv and nopv2 with an interval of 4 weeks. participants at 6 weeks of age will be enrolled and randomized to one of four arms receiving the different polio vaccines; nopv2, bopv and ipv, in different combination schedule. the target enrolment is 220 infants per arm for a total of 880. blood will be collected from all participants to measure poliovirus antibody titers to types 1, 2 and 3.

the study will assess whether adding ipv at the end of a 3-dose series of co-administered nopv2+bopv achieves at least a 95% seroconversion to all serotypes and whether adding ipv following two doses of co-administered nopv2+bopv achieves at least a 90% seroconversion to all poliovirus types. study findings will inform vaccination strategies in areas with co-circulation of poliovirus types and provide information about immunogenicity of potential routine immunization schedule with nopv2 and bopv in countries with persistent transmission or emergences of cvdpv2. this is an open-label, controlled, inequality, four arm randomized clinical trial, will be conducted in two study sites in dhaka, bangladesh. participants will be enrolled at 6 weeks of age following inclusion and exclusion criteria's, randomly assigned to one of the four study arms and followed to 18 weeks of age. three polio vaccines will be used in the study: bopv, nopv2 and ipv in different sequential or combination schedules. entry evaluations will be completed at 6 weeks of age. blood collection and study vaccine administration are planned during the study entry evaluation. post-entry evaluations and follow-up will be done at 10 weeks, 14 weeks and 18 weeks of age. blood will be collected before any study or epi vaccines are administered. presence of poliovirus neutralizing antibodies to all three poliovirus types will be assessed using a microneutralization assay.

Eligibility criteria:
inclusion criteria: 1. healthy infants 6 weeks of age 2. parents that consent for participation in the full length of the study. 3. parents that can understand and comply with planned study procedures. exclusion criteria: 1. parents and infants are unable to participate in the full length of the study 2. a diagnosis or suspicion of immunodeficiency disorder either in the infant or in an immediate family member. 3. a diagnosis or suspicion of bleeding disorder 4. acute diarrhoea, infection, or illness at the time of enrolment 5. acute vomiting and intolerance to liquids within 24 hours before the enrolment visit 6. evidence of a chronic medical condition 7. receipt of any polio vaccine (opv or ipv) before enrolment 8. known allergy/sensitivity or reaction to polio vaccine, or its contents. 9. infants from multiple births. 10. infants from premature births (\<37 weeks of gestation).

Keywords: nopv2 bopv ipv immunogenicity
botulinum toxin for stomach cancer treatment

Conditions: Stomach Neoplasms

Summary: preclinical studies at our institution, using a genetic mouse model of gastric cancer, strongly suggest that innervation of the stomach wall is required not only for the development, but also for the progression of gastric cancer, and that denervation of the stomach either by vagotomy or by injection of botulinum toxin (botox®) in the stomach wall may represent an effective therapeutic intervention. new treatment options for inoperable cancer in the stomach are urgently needed, and local treatment with botulinum toxin seems to be an attractive possibility. in this pilot study botox injections will be given by gastroscopy in both the tumor and the surrounding stomach wall. the purpose of the study is to obtain data needed to calculate sample size in a larger controlled trial.


Eligibility criteria:
inclusion criteria: patients with verified gastric adenocarcinoma but found non-resectable or inoperable after evaluation in the appropriate multidisciplinary team at st.olav hospital. trondheim university hospital. the inclusion criteria for such patients are: 1. patients who have received 1.line and 2. line chemotherapy but no longer respond to such therapy. 2. patients who, due to toxicity of chemotherapy, cannot be offered such treatment. 3. patients who, after meticulous information about chemotherapy, still do not want such treatment. 4. patients with performance status (ecog) 0-2. exclusion criteria: 1. known allergy to any of the components in botox® 2. known peripheral motor neuropathy disease ( for example: amyotrophic lateral sclerosis, als), or subclinical or clinical deficiency of neuromuscular transmission (for example: myasthenia gravis or eaton-lambert's syndrome). 3. pregnant or lactating women. 4. another cancer disease that is not under control. 5. another concomitant treatment for cancer. 6. serious mental illness. 7. performance status (ecog) 3-4.

Keywords: botulinum toxins injections stomach tomography, x-ray computed
extension study of hetrombopag in severe aplastic anemia

Conditions: Treatment-naive Severe Aplastic Anemia

Summary: this is a multicenter, placebo-control, phase 3 study of hetrombopag in patients with treatment-naive severe aplastic anemia. all subjects who have completed or withdrawn from the hr-tpo-saa-iii study will voluntarily participate in this extension study. subjects will receive the same study drug (hetrombopag or placebo) as in study hr-tpo-saa-iii, with the same doses and administration schedule or with modifications based on the actual conditions. the primary objective of this extension study is to give the subjects participating in the hr-tpo-saa-iii study the continued access to the study drug (hetrombopag or placebo) after the completion of the hr-tpo-saa-iii study.


Eligibility criteria:
inclusion criteria: 1. subjects who have completed or withdrawn from the hr-tpo-saa-iii study 2. subjects who have signed the informed consent form 3. female and male subjects of childbearing age who agree to take adequate contraceptive measures during the extension study period and within 28 days after the last dose 4. subjects who have completed the end-of-treatment evaluation in the original study exclusion criteria: 1. any unstable situation or situation that will compromise the safety of the subject 2. evidence of clonal cytogenetic abnormalities at the end-of-treatment examination of the hr-tpo-saa-iii study 3. subjects with uncontrollable hemorrhage and/or infection after standard treatment 4. subjects who have experienced deep vein thrombosis, myocardial infarction, stroke, or peripheral arterial embolism within 1 year 5. any situation that may compromise the subject and the safety or compliance thereof during the study